{"id":"W2116048670","doi":"10.1136/ard.2008.102103","title":"Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases","year":2009,"lang":"en","type":"review","venue":"Annals of the Rheumatic Diseases","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":203,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"Regeneron Pharmaceuticals; Procter and Gamble; GlaxoSmithKline; AstraZeneca; Pfizer; Amgen; Bristol-Myers Squibb; Abbott Laboratories","keywords":"Adalimumab; Medicine; Psoriatic arthritis; Ankylosing spondylitis; Population; Internal medicine; Psoriasis; Rheumatoid arthritis; Malignancy; Clinical trial; Infliximab; Mortality rate; Arthritis; Standardized mortality ratio; Disease; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02860632,0.0009103852,0.001541949,0.00311562,0.0002952368,0.001299078,0.0005349159,0.0006965708,0.00265027],"category_scores_gemma":[0.02752461,0.0003511457,0.003349839,0.002264429,0.0005158183,0.0008183031,0.001431978,0.001373962,0.0005081851],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006372416,"about_ca_system_score_gemma":0.0005401542,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003552928,"about_ca_topic_score_gemma":0.0005163121,"domain_scores_codex":[0.9794154,0.009611686,0.003503063,0.002250081,0.004699035,0.0005207161],"domain_scores_gemma":[0.9701163,0.01154537,0.01257604,0.00184809,0.003199775,0.0007145442],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"systematic_review","study_design_scores_codex":[0.03903938,0.0002978802,0.7902422,0.006360805,0.02108236,0.0003491535,0.0007337796,0.005997133,0.003304097,0.0008604539,0.006036431,0.1256964],"study_design_scores_gemma":[0.0043953,0.007604507,0.9627399,0.0005152536,0.006733786,0.001754929,0.0001287504,0.001983496,0.002321752,0.0008270121,0.0109101,0.00008509998],"study_design_candidate":"systematic_review","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"review","genre_scores_codex":[0.9271587,0.04687051,0.004398292,0.0005124254,0.0001424311,0.0009231233,0.01133083,0.0001987294,0.008464931],"genre_scores_gemma":[0.9842882,0.003212695,0.001267763,0.0002187125,0.00011378,0.0005813772,0.009553913,0.00004134579,0.0007222385],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.02860632,"threshold_uncertainty_score":0.1512864,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1709962303489945,"score_gpt":0.473548971548869,"score_spread":0.3025527411998745,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}